Zhenjing Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhenjing Jin has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Qian Zhang
Department of Hepatobiliary and Pancreatic Medicine and Interventional Medicine, The Second Hospital of Jilin University, Changchun
14 shared publicationsLanlan Yang
Department of Hepatobiliary Pancreatic Medicine and Interventional Medicine Second Hospital of Jilin University Changchun China
11 shared publicationsSiqi Liu
Department of Hepatobiliary Pancreatic Medicine and Interventional Medicine Second Hospital of Jilin University Changchun China
11 shared publicationsShengnan Jia
Department of Hepatobiliary Pancreatic Medicine and Interventional Medicine Second Hospital of Jilin University Changchun China
6 shared publicationsWenrui Wang
Department of Hepatobiliary Pancreatic Medicine and Interventional Medicine Second Hospital of Jilin University Changchun China
6 shared publicationsChen Qiu
Department of Hepatopancreatobiliary Medicine, The Second Hospital of Jilin University, Changchun City, China
5 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1772793
Significance of innate immune surveillance in emphysematous pancreatitis
Emphysematous pancreatitis (EP) is a severe and life-threatening complication of pancreatitis characterized by gas formation within pancreatic tissues, which often results from bacterial infection. This condition poses significant challenges due to its rapid progression and high mortality rate. Innate immunity plays a pivotal role in the pathogenesis, progression, and potential treatment of EP as the body’s first line of defense against infectious agents. Current research has elucidated various mechanisms through which innate immune components contribute to inflammatory responses and microbial clearance in EP. Despite advances in understanding pancreatic inflammation, the specific contributions of innate immunity to EP’s development, progression, and clinical outcomes remain not fully elucidated. Incorporating insights into innate immune markers may enhance early detection and prognostic accuracy. Moreover, therapeutic strategies targeting innate immune modulation hold promise for improving management and reducing morbidity associated with EP. This review comprehensively summarizes the mechanisms by which innate immune responses contribute to EP pathogenesis. It also highlights emerging diagnostic biomarkers and imaging techniques that facilitate early detection and discusses novel immunomodulatory therapies targeting innate immune responses. This review is a scoping review based on a structured literature search (see Methods). We aim to provide a framework and identify future research directions to improve clinical management and outcomes for patients with EP.
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1772793
Open AccessSignificance of innate immune surveillance in emphysematous pancreatitis
Emphysematous pancreatitis (EP) is a severe and life-threatening complication of pancreatitis characterized by gas formation within pancreatic tissues, which often results from bacterial infection. This condition poses significant challenges due to its rapid progression and high mortality rate. Innate immunity plays a pivotal role in the pathogenesis, progression, and potential treatment of EP as the body’s first line of defense against infectious agents. Current research has elucidated various mechanisms through which innate immune components contribute to inflammatory responses and microbial clearance in EP. Despite advances in understanding pancreatic inflammation, the specific contributions of innate immunity to EP’s development, progression, and clinical outcomes remain not fully elucidated. Incorporating insights into innate immune markers may enhance early detection and prognostic accuracy. Moreover, therapeutic strategies targeting innate immune modulation hold promise for improving management and reducing morbidity associated with EP. This review comprehensively summarizes the mechanisms by which innate immune responses contribute to EP pathogenesis. It also highlights emerging diagnostic biomarkers and imaging techniques that facilitate early detection and discusses novel immunomodulatory therapies targeting innate immune responses. This review is a scoping review based on a structured literature search (see Methods). We aim to provide a framework and identify future research directions to improve clinical management and outcomes for patients with EP.
- Open Access
- 16 July 2026
- Published by Wiley in Cancer Science
- Vol. 117 (10) , 2705-2718
Indole‐3‐Propionic Acid Drives Dendritic H3K27 Acetylation to Enhance CD8 + T Cell Immunity in Hepatocellular Carcinoma
Indole‐3‐propionic acid (IPA) is documented to improve the effectiveness of tumor immunotherapy via regulating anti‐tumor immunity. However, the impacts of IPA in hepatocellular carcinoma (HCC) patients undergoing sintilimab combined with bevacizumab (SCB) treatment remain unknown. This study investigated the effects and underlying mechanisms of IPA in SCB‐treated HCC. Serum, tumor tissue, fecal and lymph node tissue samples were collected from HCC patients with or without a response to SCB therapy. Humanized orthotopic and subcutaneous HCC NOG mouse models were established. IPA‐treated mouse dendritic cells (DCs) were co‐cultured with mouse CD8 + T‐cells, which were subsequently co‐cultured with Hepa1‐6 cells. IPA levels were elevated in the serum, tumor tissues, and feces of responders, and serum IPA levels were positively correlated with the proportion of IFN‐γ + CD8 + T cells in tumor tissues as well asac‐H3K27 and IL‐12A levels in lymph node DCs. IPA amplified the suppressive impact of SCB on tumor growth in HCC mice. Moreover, IPA increased ac‐H3K27 and IL‐12A levels in DCs and upregulated effector CD8 + T‐cell immunity in HCC mice. Administration of a CD8‐neutralizing antibody and injection of shIL‐12A‐transfected DCs weakened IPA‐mediated inhibition of HCC in vivo. Furthermore, the ac‐H3K27 inhibitor A‐485 suppressed IL‐12A expression and effector CD8 + T‐cell immunity induced by IPA, thereby promoting the proliferation, invasion, and migration of Hepa1‐6 cells in vitro. These findings demonstrate that IPA enhances the effect of SCB‐treated HCC by upregulating H3K27 acetylation to promote IL‐12A expression in DCs, thereby potentiating CD8 + T‐cell immunity, which provides a basis for its potential use as a clinical adjuvant therapy.
- 16 July 2026
- Published by Wiley in Cancer Science
- Vol. 117 (10) , 2705-2718
Open AccessIndole‐3‐Propionic Acid Drives Dendritic H3K27 Acetylation to Enhance CD8 + T Cell Immunity in Hepatocellular Carcinoma
Indole‐3‐propionic acid (IPA) is documented to improve the effectiveness of tumor immunotherapy via regulating anti‐tumor immunity. However, the impacts of IPA in hepatocellular carcinoma (HCC) patients undergoing sintilimab combined with bevacizumab (SCB) treatment remain unknown. This study investigated the effects and underlying mechanisms of IPA in SCB‐treated HCC. Serum, tumor tissue, fecal and lymph node tissue samples were collected from HCC patients with or without a response to SCB therapy. Humanized orthotopic and subcutaneous HCC NOG mouse models were established. IPA‐treated mouse dendritic cells (DCs) were co‐cultured with mouse CD8 + T‐cells, which were subsequently co‐cultured with Hepa1‐6 cells. IPA levels were elevated in the serum, tumor tissues, and feces of responders, and serum IPA levels were positively correlated with the proportion of IFN‐γ + CD8 + T cells in tumor tissues as well asac‐H3K27 and IL‐12A levels in lymph node DCs. IPA amplified the suppressive impact of SCB on tumor growth in HCC mice. Moreover, IPA increased ac‐H3K27 and IL‐12A levels in DCs and upregulated effector CD8 + T‐cell immunity in HCC mice. Administration of a CD8‐neutralizing antibody and injection of shIL‐12A‐transfected DCs weakened IPA‐mediated inhibition of HCC in vivo. Furthermore, the ac‐H3K27 inhibitor A‐485 suppressed IL‐12A expression and effector CD8 + T‐cell immunity induced by IPA, thereby promoting the proliferation, invasion, and migration of Hepa1‐6 cells in vitro. These findings demonstrate that IPA enhances the effect of SCB‐treated HCC by upregulating H3K27 acetylation to promote IL‐12A expression in DCs, thereby potentiating CD8 + T‐cell immunity, which provides a basis for its potential use as a clinical adjuvant therapy.
- Open Access
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1706013
Association between metabolic syndrome, fatty liver disease, and gastrointestinal tumors: a population-based study with external validation
Background: Metabolic Syndrome (MetS), defined by central obesity and disturbances in glucose and lipid metabolism, has not been extensively validated in large national cohorts concerning its association with fatty liver disease (FLD), gastrointestinal tumors (GIT), and prognostic outcomes. Methods: A total of 24,434 adults from the 2003–2018 cycles of The National Health and Nutrition Examination Survey (NHANES) were included as the development cohort, with a validation cohort of 365 adults to verify key associations. MetS was diagnosed per NCEP-ATP III criteria across both cohorts. Weighted multivariate regression models assessed associations between MetS and FLD/GIT incidence, and Cox proportional hazards models evaluated survival risks. Three hierarchical models were constructed: Model 1 (unadjusted), Model 2 (adjusted for demographic confounders), and Model 3 (further adjusted for laboratory parameters). Results: In the development cohort, MetS patients exhibited a higher FLD prevalence (16.2% vs. 4.6%) and GIT incidence (1.25% vs. 0.57%). After full adjustment in Model 3, MetS remained a strong independent risk factor for FLD (OR = 3.889, 95% CI: 3.529–4.307) and GIT (OR = 2.456, 95% CI: 1.832–3.292). These associations were corroborated in the validation cohort, with adjusted ORs of 4.760 for FLD and 4.395 for GIT. Survival analysis indicated that MetS significantly reduced overall survival in the development cohort, with HRs for all-cause, cancer-specific, and cardiovascular mortality of 2.146, 1.941, and 2.572, respectively. Furthermore, the mortality risk was further elevated in FLD patients with MetS (all-cause mortality HR = 1.823). In the validation cohort, cardiovascular mortality risk was significant (HR = 3.902), while other survival outcomes did not reach statistical significance due to the small sample size. Sensitivity analysis using IDF criteria confirmed the robustness of these findings. Conclusion: This study confirms that MetS is strongly associated with FLD risk and GIT incidence, supporting early metabolic intervention to interrupt the progression of liver disease and tumors.
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1706013
Open AccessAssociation between metabolic syndrome, fatty liver disease, and gastrointestinal tumors: a population-based study with external validation
Background: Metabolic Syndrome (MetS), defined by central obesity and disturbances in glucose and lipid metabolism, has not been extensively validated in large national cohorts concerning its association with fatty liver disease (FLD), gastrointestinal tumors (GIT), and prognostic outcomes. Methods: A total of 24,434 adults from the 2003–2018 cycles of The National Health and Nutrition Examination Survey (NHANES) were included as the development cohort, with a validation cohort of 365 adults to verify key associations. MetS was diagnosed per NCEP-ATP III criteria across both cohorts. Weighted multivariate regression models assessed associations between MetS and FLD/GIT incidence, and Cox proportional hazards models evaluated survival risks. Three hierarchical models were constructed: Model 1 (unadjusted), Model 2 (adjusted for demographic confounders), and Model 3 (further adjusted for laboratory parameters). Results: In the development cohort, MetS patients exhibited a higher FLD prevalence (16.2% vs. 4.6%) and GIT incidence (1.25% vs. 0.57%). After full adjustment in Model 3, MetS remained a strong independent risk factor for FLD (OR = 3.889, 95% CI: 3.529–4.307) and GIT (OR = 2.456, 95% CI: 1.832–3.292). These associations were corroborated in the validation cohort, with adjusted ORs of 4.760 for FLD and 4.395 for GIT. Survival analysis indicated that MetS significantly reduced overall survival in the development cohort, with HRs for all-cause, cancer-specific, and cardiovascular mortality of 2.146, 1.941, and 2.572, respectively. Furthermore, the mortality risk was further elevated in FLD patients with MetS (all-cause mortality HR = 1.823). In the validation cohort, cardiovascular mortality risk was significant (HR = 3.902), while other survival outcomes did not reach statistical significance due to the small sample size. Sensitivity analysis using IDF criteria confirmed the robustness of these findings. Conclusion: This study confirms that MetS is strongly associated with FLD risk and GIT incidence, supporting early metabolic intervention to interrupt the progression of liver disease and tumors.
- Open Access
- 3 February 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Association of atherogenic index of plasma and cardiometabolic index with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999–2018
The atherogenic index of plasma (AIP) serves as a crucial indicator for assessing atherosclerotic risk. It reflects the degree of dyslipidaemia and cardiov
- 3 February 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Open AccessAssociation of atherogenic index of plasma and cardiometabolic index with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999–2018
The atherogenic index of plasma (AIP) serves as a crucial indicator for assessing atherosclerotic risk. It reflects the degree of dyslipidaemia and cardiov
- Open Access
- 31 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1510770
Autoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations
In recent years, the novel coronavirus infectious disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to over 670 million infections and nearly 7 million deaths worldwide. The global pandemic of COVID-19 has precipitated a significant public health crisis. The prevalence of liver function abnormalities associated with SARS-CoV-2 is as high as 53% among healthy individuals or patients with autoimmune hepatitis (AIH) and shows a positive correlation with disease severity; moreover, specific adaptive immune responses can influence the trajectory and outcomes of COVID-19. For instance, SARS-CoV-2 may impact autoimmunity through mechanisms such as excessive stimulation of immune responses and molecular mimicry, particularly in genetically predisposed individuals. Currently, the overall mutational trend of SARS-CoV-2 indicates heightened infectivity and immune evasion capabilities. Consequently, vaccination remains crucial for universal protection against this disease. Nevertheless, alongside the widespread implementation of vaccination programs globally, an increasing number of cases have been documented where COVID-19 vaccination appears to trigger new-onset autoimmune hepatitis; yet definitive evidence is still pending elucidation regarding causality. In this review, we analyse the clinical-immunological characteristics, risks associated with severe disease progression, and prognosis for AIH patients infected with SARS-CoV-2; discuss the detrimental effects exerted by SARS-CoV-2 on hepatic function; summarise the mechanisms and attributes leading to new-onset AIH; as well as provide insights into how vaccination may interfere with autoimmunity processes. We continue to underscore the significance of vaccination while aiming to enhance awareness concerning potential risks associated with it—this could facilitate better management strategies for autoimmune diseases along with appropriate adjustments in vaccination protocols. Although the precise triggering mechanism linking COVID-19-related events to AIH remains unclear, existing evidence suggests that this relationship is far from coincidental.
- 31 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1510770
Open AccessAutoimmune hepatitis under the COVID-19 veil: an analysis of the nature of potential associations
In recent years, the novel coronavirus infectious disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to over 670 million infections and nearly 7 million deaths worldwide. The global pandemic of COVID-19 has precipitated a significant public health crisis. The prevalence of liver function abnormalities associated with SARS-CoV-2 is as high as 53% among healthy individuals or patients with autoimmune hepatitis (AIH) and shows a positive correlation with disease severity; moreover, specific adaptive immune responses can influence the trajectory and outcomes of COVID-19. For instance, SARS-CoV-2 may impact autoimmunity through mechanisms such as excessive stimulation of immune responses and molecular mimicry, particularly in genetically predisposed individuals. Currently, the overall mutational trend of SARS-CoV-2 indicates heightened infectivity and immune evasion capabilities. Consequently, vaccination remains crucial for universal protection against this disease. Nevertheless, alongside the widespread implementation of vaccination programs globally, an increasing number of cases have been documented where COVID-19 vaccination appears to trigger new-onset autoimmune hepatitis; yet definitive evidence is still pending elucidation regarding causality. In this review, we analyse the clinical-immunological characteristics, risks associated with severe disease progression, and prognosis for AIH patients infected with SARS-CoV-2; discuss the detrimental effects exerted by SARS-CoV-2 on hepatic function; summarise the mechanisms and attributes leading to new-onset AIH; as well as provide insights into how vaccination may interfere with autoimmunity processes. We continue to underscore the significance of vaccination while aiming to enhance awareness concerning potential risks associated with it—this could facilitate better management strategies for autoimmune diseases along with appropriate adjustments in vaccination protocols. Although the precise triggering mechanism linking COVID-19-related events to AIH remains unclear, existing evidence suggests that this relationship is far from coincidental.
- Open Access
- 15 January 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1493439
The neutrophil–lymphocyte ratio as a risk factor for all-cause mortality among individuals with resolved HBV infection: evidence from the NHANES 1999–2018
Background: Inflammation is a critical component in the process of resolved hepatitis B virus (HBV) infection. The neutrophil-to-lymphocyte ratio (NLR) serves as a sensitive indicator of systemic inflammation and immune activation. Our study aimed to investigate the correlation between elevated NLR levels and the risk of all-cause mortality in patients with resolved HBV infection. Additionally, we evaluated the potential mediating effect of diabetes mellitus (DM) on this correlation.Methods: Our study enrolled 1,146 adult patients with resolved HBV infection from the National Health and Nutrition Examination Survey (NHANES) between 1999 and 2018. We utilized the Restricted Cubic Splines (RCS) and Maximum Selection Rank Statistical Method (MSRSM) to analyze the relationship between the NLR and the risk of all-cause mortality. The impact of NLR was evaluated using a weighted multivariate Cox regression model, and the model’s predictive accuracy was assessed using time-dependent Receiver Operating Characteristic (ROC) curves. An intermediary analysis was conducted to explore the potential influence of DM on the observed relationship.Results: During follow-up period of 103.54 ± 4.90 months, we recorded 207 deaths among the study participants. The analysis using the RCS method revealed a significant positive correlation between the NLR and the risk of all-cause mortality. Those with elevated NLR levels faced a substantially higher mortality risk compared to those with lower levels, as indicated by a Hazard Ratio (HR) of 1.84, with a 95% Confidence Interval (CI) of 1.17 to 2.89 (p < 0.05). The predictive accuracy of the model was substantial, as evidenced by the Area Under the Curve (AUC) for ROC curves at 3, 5, and 10 years, which were 0.873, 0.870, and 0.862, respectively. Furthermore, mediation analysis indicated that DM significantly influenced the relationship between the NLR and mortality, with a mediation effect of 6.57% (95% Confidence Interval [CI]: 0.64 to 15%; p = 0.02).Conclusion: Elevated NLR is significantly associated with an increased risk of all-cause mortality in patients with resolved HBV infection. Concurrently, DM acts as a partial mediator of this association.
- 15 January 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 12, 1493439
Open AccessThe neutrophil–lymphocyte ratio as a risk factor for all-cause mortality among individuals with resolved HBV infection: evidence from the NHANES 1999–2018
Background: Inflammation is a critical component in the process of resolved hepatitis B virus (HBV) infection. The neutrophil-to-lymphocyte ratio (NLR) serves as a sensitive indicator of systemic inflammation and immune activation. Our study aimed to investigate the correlation between elevated NLR levels and the risk of all-cause mortality in patients with resolved HBV infection. Additionally, we evaluated the potential mediating effect of diabetes mellitus (DM) on this correlation.Methods: Our study enrolled 1,146 adult patients with resolved HBV infection from the National Health and Nutrition Examination Survey (NHANES) between 1999 and 2018. We utilized the Restricted Cubic Splines (RCS) and Maximum Selection Rank Statistical Method (MSRSM) to analyze the relationship between the NLR and the risk of all-cause mortality. The impact of NLR was evaluated using a weighted multivariate Cox regression model, and the model’s predictive accuracy was assessed using time-dependent Receiver Operating Characteristic (ROC) curves. An intermediary analysis was conducted to explore the potential influence of DM on the observed relationship.Results: During follow-up period of 103.54 ± 4.90 months, we recorded 207 deaths among the study participants. The analysis using the RCS method revealed a significant positive correlation between the NLR and the risk of all-cause mortality. Those with elevated NLR levels faced a substantially higher mortality risk compared to those with lower levels, as indicated by a Hazard Ratio (HR) of 1.84, with a 95% Confidence Interval (CI) of 1.17 to 2.89 (p < 0.05). The predictive accuracy of the model was substantial, as evidenced by the Area Under the Curve (AUC) for ROC curves at 3, 5, and 10 years, which were 0.873, 0.870, and 0.862, respectively. Furthermore, mediation analysis indicated that DM significantly influenced the relationship between the NLR and mortality, with a mediation effect of 6.57% (95% Confidence Interval [CI]: 0.64 to 15%; p = 0.02).Conclusion: Elevated NLR is significantly associated with an increased risk of all-cause mortality in patients with resolved HBV infection. Concurrently, DM acts as a partial mediator of this association.
- 20 February 2024
- Vol. 32 (2) , 173-179
[New progress in the first-line treatment of advanced hepatocellular carcinoma].
Hepatocellular carcinoma is a kind of cancer with a strong invasion, a high incidence rate and mortality, and a poor prognosis. At the time of diagnosis, most patients are already in the advanced stages of a tumor and have lost the chance for radical surgical treatment. Advanced hepatocellular carcinoma treatment has a gradual transition from systemic chemotherapy to targeted therapy, immunotherapy, and combination therapy, especially immune checkpoint inhibitor-based immunotherapy combination therapy, such as combination with bevacizumab monoclonal antibodies and other drugs, or combination with TACE, HAIC, radiotherapy, ablation, and other treatment methods. Combination therapy has significant synergistic effects and thus has already become a future treatment trend for hepatocellular carcinoma. An immunotherapy-based combination therapy plan will run through the whole process of systemic therapy, which is expected to bring better survival benefits to patients with hepatocellular carcinoma. This article reviews the latest research progress in aspects of the first-line treatment of advanced hepatocellular carcinoma.
- 20 February 2024
- Vol. 32 (2) , 173-179
[New progress in the first-line treatment of advanced hepatocellular carcinoma].
Hepatocellular carcinoma is a kind of cancer with a strong invasion, a high incidence rate and mortality, and a poor prognosis. At the time of diagnosis, most patients are already in the advanced stages of a tumor and have lost the chance for radical surgical treatment. Advanced hepatocellular carcinoma treatment has a gradual transition from systemic chemotherapy to targeted therapy, immunotherapy, and combination therapy, especially immune checkpoint inhibitor-based immunotherapy combination therapy, such as combination with bevacizumab monoclonal antibodies and other drugs, or combination with TACE, HAIC, radiotherapy, ablation, and other treatment methods. Combination therapy has significant synergistic effects and thus has already become a future treatment trend for hepatocellular carcinoma. An immunotherapy-based combination therapy plan will run through the whole process of systemic therapy, which is expected to bring better survival benefits to patients with hepatocellular carcinoma. This article reviews the latest research progress in aspects of the first-line treatment of advanced hepatocellular carcinoma.
- Open Access
Immunoglobulin G4‐related disease: Multiple organ occupation on CT
One case involved a 61‐year‐old woman who was admitted to hospital with liver occupation, subsequently found multiple organ occupation, and was eventually pathologically identified as having immunoglobulin G4‐related disease.
Open AccessImmunoglobulin G4‐related disease: Multiple organ occupation on CT
One case involved a 61‐year‐old woman who was admitted to hospital with liver occupation, subsequently found multiple organ occupation, and was eventually pathologically identified as having immunoglobulin G4‐related disease.
- Open Access
- 20 October 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (10) , e8044
A case of hemophagocytic syndrome secondary to B‐cell lymphoma
Key Clinical Message: In this report we highlight a case of HPS secondary to B‐cell lymphoma, aiming to facilitate the early recognition and treatment of HPS in its classic presentation by clinicians.
- 20 October 2023
- Published by Wiley in Clinical Case Reports
- Vol. 11 (10) , e8044
Open AccessA case of hemophagocytic syndrome secondary to B‐cell lymphoma
Key Clinical Message: In this report we highlight a case of HPS secondary to B‐cell lymphoma, aiming to facilitate the early recognition and treatment of HPS in its classic presentation by clinicians.